RSS-Feed abonnieren
DOI: 10.1055/s-2006-946706
Bupropion Augmentation in the Treatment of Chronic Fatigue Syndrome with Coexistent Major Depression Episode
A Case ReportPublikationsverlauf
Received: 16.1.2006
Revised: 2.3.2006
Accepted: 13.3.2006
Publikationsdatum:
27. Juli 2006 (online)
![](https://www.thieme-connect.de/media/pharmaco/200604/lookinside/thumbnails/10.1055-s-2006-946706-1.jpg)
While psychoeducational strategies and general support are always indicated for the treatment of chronic fatigue syndrome (CFS), pharmacological strategies are yet not well established. Antidepressants such as selective serotonin re-uptake inhibitors have been shown to influence positively symptoms and immunological parameters. However, a considerable part of CFS patients do not satisfactorily respond to them. Bupropion, a centrally acting catecholamine-transporter blocker without classic psycho-analeptic properties, shows theoretical potential to improve fatigue symptoms. In the reported case paroxetine was augmented with bupropion at high dosage, a strategy which consecutively led to a rapid relief of CFS-symptoms.
References
- 1 Ascher J A, Cole J O, Colin J N, Feighner J P, Ferris R M, Fibiger H C. et al . Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995; 56 395-401
- 2 Bruera E, Driver L, Barnes E A, Willey J, Shen L, Palmer J L. et al . Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003; 21 4439-4443
- 3 Carruthers B M, Jain A K, De Meirleir K L, Peterson D L, Klimas N G, Lerner A M. et al . ME/CFS: clinical working case definition, diagnostic and treatment protocols. J Chron Fatigue Syndrome. 2003; 11 1-97
- 4 Cleare A J, Messa C, Rabiner E A, Grasby P M. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100 635. Biol Psychiatry. 2005; 57 239-246
- 5 Craig T, Kakumanu S. Chronic fatigue syndrome: evaluation and treatment. Am Fam Physician. 2002; 65 1083-1090
- 6 Cullum J L, Wojciechowski A E, Pelletier G, Simpson J S. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004; 49 139-144
- 7 Fishbain D A, Cutler R B, Lewis J, Cole B, Rosomoff H L, Steele-Rosomoff R. Modafinil for the treatment of pain-associated fatigue: review and case report. J Pain Palliat Care Pharmacother. 2004; 18 39-47
- 8 Fukuda K, Straus S E, Hickie I, Sharpe M C, Dobbins J G, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994; 121 953-959
- 9 Goodnick P J, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry. 1993; 54 13-20
- 10 Goodnick P J, Sandoval R, Brickman A, Klimas N G. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry. 1992; 32 834-838
- 11 Holmes G P, Kaplan J E, Gantz N M, Komaroff A L, Schonberger L B, Straus S E. et al . Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988; 108 387-389
- 12 Sharpe M C, Archard L C, Banatvala J E, Borysiewicz L K, Clare A W, David A. et al . A report-chronic fatigue syndrome: guidelines for research. J R Soc Med. 1991; 84 118-121
- 13 Steele L, Dobbins J G, Fukuda K, Reyes M, Randall B, Koppelman M. et al . The epidemiology of chronic fatigue in San Francisco. Am J Med. 1998; 105 (3A) 83S-90S
- 14 Turkington D, Hedwat D, Rider I, Young A H. Recovery from chronic fatigue syndrome with modafinil. Hum Psychopharmacol. 2004; 19 63-64
Dr. med. Carlos Schönfeldt-Lecuona, MD
University of Ulm
Dep. of Psychiatry III
Leimgrubenweg 12-14
89075 Ulm
Germany
Telefon: +49 731 500 21499
Fax: +49 731 500 26751
eMail: carlos.schoenfeldt@uni-ulm.de